The article reports a 54% drop in coughing under usual care that followed treatment guidelines. That is the clearest everyday takeaway for the Chronic Cough community. The Pulmonology Today article reviews a mixed moment for cough care. It describes growing recognition of persistent cough as a disease. It also reports the failure of CALM, a study program testing camlipixant. That is a drug being developed for cough that persists despite treatment. Alongside that setback, the article highlights results from ordinary guideline-based care. This means care following established treatment recommendations. It cites PROCOUGH, a study following people with persistent cough. The reported 54% reduction offers a useful counterpoint to the drug news. A failed drug program does not mean existing care offers no benefit. Still, the supplied excerpt leaves important gaps. It does not give the number of people studied or follow-up length. It also does not detail which treatments people received. So that percentage is not a forecast for any one member. Nor does it show that usual care outperformed camlipixant in a direct comparison. For members tracking their own cough, the useful theme is change over time. A shared log could include cough counts, tracking times, and treatment changes. Notes about how coughing affects daily life can add context. Comparing similar time periods makes community updates easier to understand. Sharing how you counted matters as much as sharing the final number. What changes have you seen in your cough over time, and how have you tracked them?